Promising combo trial for prostate cancer halted early

This study tested a combination of two drugs—tivozanib and enzalutamide—in men with advanced prostate cancer that had stopped responding to standard hormone therapy. Enzalutamide blocks male hormones that fuel cancer growth, while tivozanib cuts off the tumor's blood supply. The goal was to see if the combo could delay cancer progression longer than enzalutamide alone. However, the trial was terminated early after enrolling only 5 participants, so the results are not conclusive.